Serine
Serine is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against interleukin-17A. In addition, it is known to target metabotropic glutamate receptor 4, probable G-protein coupled receptor 34, probable G-protein coupled receptor 174, metabotropic glutamate receptor 6, neutral amino acid transporter B(0), G-protein coupled receptor family C group 6 member A, sodium- and chloride-dependent glycine transporter 2, glutamate receptor ionotropic, NMDA 1, potassium voltage-gated channel subfamily A member 1, glutamate receptor ionotropic, NMDA 2D, glutamate receptor ionotropic, NMDA 2A, metabotropic glutamate receptor 8, metabotropic glutamate receptor 7, toll-like receptor 4, glutamate receptor ionotropic, NMDA 2C, and glutamate receptor ionotropic, NMDA 2B.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
42 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tourette syndrome | D005879 | EFO_0004895 | F95.2 | — | — | — | 1 | — | 1 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | — | 1 | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | 1 | 2 | — | — | — | 2 |
| Cerebral hemorrhage | D002543 | — | 1 | — | — | — | 1 | ||
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | — | — | — | 1 |
| Cocaine-related disorders | D019970 | F14 | — | 1 | — | — | — | 1 | |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | 1 | — | — | — | 1 |
| Hereditary sensory and autonomic neuropathies | D009477 | 1 | 1 | — | — | — | 1 | ||
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 1 | — | — | — | 1 |
| Coronary artery disease | D003324 | I25.1 | — | 1 | — | — | — | 1 | |
| Unstable angina | D000789 | EFO_1000985 | I20.0 | — | 1 | — | — | — | 1 |
| Coronary restenosis | D023903 | EFO_0004224 | — | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 1 | — | — | — | 2 | 3 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | — | — | — | — | 1 | 1 |
| Crohn disease | D003424 | EFO_0000384 | K50 | — | — | — | — | 1 | 1 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | — | 1 | 1 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | — | — | 1 | 1 |
| Postoperative cognitive complications | D000079690 | — | — | — | — | 1 | 1 | ||
| Tic disorders | D013981 | F95 | — | — | — | — | 1 | 1 | |
| Tardive dyskinesia | D000071057 | G24.01 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | SERINE |
| INN | dexfosfoserine |
| Description | L-serine is the L-enantiomer of serine. It has a role as a human metabolite, an algal metabolite, a Saccharomyces cerevisiae metabolite, an Escherichia coli metabolite and a mouse metabolite. It is a serine family amino acid, a proteinogenic amino acid, a L-alpha-amino acid and a serine. It is a conjugate base of a L-serinium. It is a conjugate acid of a L-serinate. It is an enantiomer of a D-serine. It is a tautomer of a L-serine zwitterion. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | N[C@@H](CO)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 56-45-1 |
| RxCUI | 9671 |
| ChEMBL ID | CHEMBL11298 |
| ChEBI ID | 17115 |
| PubChem CID | 5951 |
| DrugBank | DB00133 |
| UNII ID | VI4F0K069V (ChemIDplus, GSRS) |
Target
Agency Approved
IL17A
IL17A
Organism
Homo sapiens
Gene name
IL17A
Gene synonyms
CTLA8, IL17
NCBI Gene ID
Protein name
interleukin-17A
Protein synonyms
CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, cytotoxic T-lymphocyte-associated protein 8, interleukin 17 (cytotoxic T-lymphocyte-associated serine esterase 8), interleukin-17
Uniprot ID
Mouse ortholog
Il17a (16171)
interleukin-17A (Q62386)
Alternate
GRM4
GRM4
GPR34
GPR34
GPR174
GPR174
GRM6
GRM6
SLC1A5
SLC1A5
GPRC6A
GPRC6A
SLC6A5
SLC6A5
GRIN1
GRIN1
KCNA1
KCNA1
GRIN2D
GRIN2D
GRIN2A
GRIN2A
GRM8
GRM8
GRM7
GRM7
TLR4
TLR4
GRIN2C
GRIN2C
GRIN2B
GRIN2B
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 490,290 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,573 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more